Registro:

Referencias:

• Bevan, J.S., Webster, J., Burke, C.W., Scanlon, M.F., Dopamine agonists and pituitary tumor shrinkage (1992) Endocr Rev, 13, pp. 220-240
• Bevan, J.S., The antitumoral effects of somatostatin analog therapy in acromegaly (2005) J Clin Endocrinol Metab, 90, pp. 1856-1863
• Melmed, S., Sternberg, R., Cook, D., Klibanski, A., Chanson, P., Bonert, V., Vance, M.L., Barkan, A., A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly (2005) J Clin Endocrinol Metab, 90, pp. 4405-4410
• Pivonello, R., Ferone, D., De Herder, W.W., De Krijger, R.R., Waaijers, M., Mooij, D.M., Van Koetsveld, P.M., Hofland, L.J., Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors (2004) J Clin Endocrinol Metab, 89, pp. 4493-4502
• Boscaro, M., Barzon, L., Fallo, F., Sonino, N., Cushing's syndrome (2001) Lancet, 357, pp. 783-791
• De Herder, W.W., Lamberts, S.W., Octapeptide somatostatin-analogue therapy of Cushing's syndrome (1999) Postgrad Med J, 75, pp. 65-66
• Melmed, S., Mechanisms for pituitary tumorigenesis: The plastic pituitary (2003) J Clin Invest, 112, pp. 1603-1618
• Dahia, P.L., Grossman, A.B., The molecular pathogenesis of corticotroph tumors (1999) Endocr Rev, 20, pp. 136-155
• Colao, A., Di Sarno, A., Marzullo, P., Di Somma, C., Cerbone, G., Landi, M.L., Faggiano, A., Lombardi, G., New medical approaches in pituitary adenomas (2000) Horm Res, 53 (3 SUPPL.), pp. 76-87
• Newell-Price, J., Bertagna, X., Grossman, A.B., Nieman, L.K., Cushing's syndrome (2006) Lancet, 367, pp. 1605-1617
• Newell-Price, J., Trainer, P., Besser, M., Grossman, A., The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states (1998) Endocr Rev, 19, pp. 647-672
• Arnaldi, G., Angeli, A., Atkinson, A.B., Bertagna, X., Cavagnini, F., Chrousos, G.P., Fava, G.A., Boscaro, M., Diagnosis and complications of Cushing's syndrome: A consensus statement (2003) J Clin Endocrinol Metab, 88, pp. 5593-5602
• Nieman, L.K., Medical therapy of Cushing's disease (2002) Pituitary, 5, pp. 77-82
• Morris, D., Grossman, A., The medical management of Cushing's syndrome (2002) Ann NY Acad Sci, 970, pp. 119-133
• Heaney, A.P., Fernando, M., Yong, W.H., Melmed, S., Functional PPAR-γ receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas (2002) Nat Med, 8, pp. 1281-1287
• Ambrosi, B., Dall'Asta, C., Cannavo, S., Libe, R., Vigo, T., Epaminonda, P., Chiodini, I., Beck-Peccoz, P., Effects of chronic administration of PPAR-γ ligand rosiglitazone in Cushing's disease (2004) Eur J Endocrinol, 151, pp. 173-178
• Kurie, J.M., The biologic basis for the use of retinoids in cancer prevention and treatment (1999) Curr Opin Oncol, 11, pp. 497-502
• Merino, R., Hurle, J.M., The molecular basis of retinoid action in tumors (2003) Trends Mol Med, 9, pp. 509-511
• Lotan, R., Retinoids in cancer chemoprevention (1996) FASEB J, 10, pp. 1031-1039
• Kang, H.J., Song, M.R., Lee, S.K., Shin, E.C., Choi, Y.H., Kim, S.J., Lee, J.W., Lee, M.O., Retinoic acid and its receptors repress the expression and transactivation functions of Nur77: A possible mechanism for the inhibition of apoptosis by retinoic acid (2000) Exp Cell Res, 256, pp. 545-554
• Fanjul, A., Dawson, M.I., Hobbs, P.D., Jong, L., Cameron, J.F., Harlev, E., Graupner, G., Pfahl, M., A new class of retinoids with selective inhibition of AP-1 inhibits proliferation (1994) Nature, 372, pp. 107-111
• Kovalovsky, D., Refojo, D., Liberman, A.C., Hochbaum, D., Pereda, M.P., Coso, O.A., Stalla, G.K., Arzt, E., Activation and induction of NUR77/NURR1 in corticotrophs by CRH/cAMP: Involvement of calcium, protein kinase A, and MAPK pathways (2002) Mol Endocrinol, 16, pp. 1638-1651
• Maira, M., Martens, C., Philips, A., Drouin, J., Heterodimerization between members of the Nur subfamily of orphan nuclear receptors as a novel mechanism for gene activation (1999) Mol Cell Biol, 19, pp. 7549-7557
• Philips, A., Lesage, S., Gingras, R., Maira, M.H., Gauthier, Y., Hugo, P., Drouin, J., Novel dimeric Nur77 signaling mechanism in endocrine and lymphoid cells (1997) Mol Cell Biol, 17, pp. 5946-5951
• Paez-Pereda, M., Kovalovsky, D., Hopfner, U., Theodoropoulou, M., Pagotto, U., Uhl, E., Losa, M., Stalla, G.K., Retinoic acid prevents experimental Cushing syndrome (2001) J Clin Invest, 108, pp. 1123-1131
• Lindblad-Toh, K., Wade, C.M., Mikkelsen, T.S., Karlsson, E.K., Jaffe, D.B., Kamal, M., Clamp, M., Fitzgerald, M., Genome sequence, comparative analysis and haplotype structure of the domestic dog (2005) Nature, 438, pp. 803-819
• Ling, G.V., Stabenfeldt, G.H., Comer, K.M., Gribble, D.H., Schechter, R.D., Canine hyperadrenocorticism: Pretreatment clinical and laboratory evaluation of 117 cases (1979) J Am Vet Med Assoc, 174, pp. 1211-1215
• Feldman, E.C., Bruyette, D.S., Nelson, R.W., Farver, T.B., Plasma cortisol response to ketoconazole administration in dogs with hyperadrenocorticism (1990) J Am Vet Med Assoc, 197, pp. 71-78
• Wei, L.N., Retinoid receptors and their coregulators (2003) Annu Rev Pharmacol Toxicol, 43, pp. 47-72
• Rijnberk, A., Van Wees, A., Mol, J.A., Assessment of two tests for the diagnosis of canine hyperadrenocorticism (1988) Vet Rec, 122, pp. 178-180
• Orth, D.N., Peterson, M.E., Drucker, W.D., Plasma immunoreactive proopiomelanocortin peptides and cortisol in normal dogs and dogs with Cushing's syndrome: Diurnal rhythm and responses to various stimuli (1988) Endocrinology, 122, pp. 1250-1262
• Muller, O.A., Stalla, G.K., Von Werder, K., Corticotropin releasing factor: A new tool for the differential diagnosis of Cushing's syndrome (1983) J Clin Endocrinol Metab, 57, pp. 227-229
• Bosje, J.T., Rijnberk, A., Mol, J.A., Voorhout, G., Kooistra, H.S., Plasma concentrations of ACTH precursors correlate with pituitary size and resistance to dexamethasone in dogs with pituitary-dependent hyperadrenocorticism (2002) Domest Anim Endocrinol, 22, pp. 201-210
• Tanaka, S., Comparative aspects of intracellular proteolytic processing of peptide hormone precursors: Studies of proopiomelanocortin processing (2003) Zoolog Sci, 20, pp. 1183-1198
• Ross, E.J., Linch, D.C., Cushing's syndrome - Killing disease: Discriminatory value of signs and symptoms aiding early diagnosis (1982) Lancet, 2, pp. 646-649
• Lado-Abeal, J., Rodriguez-Arnao, J., Newell-Price, J.D., Perry, L.A., Grossman, A.B., Besser, G.M., Trainer, P.J., Menstrual abnormalities in women with Cushing's disease are correlated with hypercortisolemia rather than raised circulating androgen levels (1998) J Clin Endocrinol Metab, 83, pp. 3083-3088
• Gearing, K.L., Gottlicher, M., Teboul, M., Widmark, E., Gustafsson, J.A., Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor (1993) Proc Natl Acad Sci USA, 90, pp. 1440-1444
• Beale, E.G., Hammer, R.E., Antoine, B., Forest, C., Disregulated glyceroneogenesis: PCK1 as a candidate diabetes and obesity gene (2004) Trends Endocrinol Metab, 15, pp. 129-135

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------